Xbrane Biopharma Q2’22: Xlucane™ Launch Anticipated to Q1’23

Research Note

2022-07-22

13:40

Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European launch of Xlucane™, anticipated in Q1 2023.

Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.